Nicolas Hohmann

TL;DR: Myrcludex B showed excellent tolerability up to high doses and Pharmacologic properties followed a 2-compartment target-mediated drug disposition model, vital for planning of further multiple dose efficacy trials in patients.

TL;DR: Young persons who present with agitation and cardiovascular and/or psychiatric manifestations of unclear origin and whose drug screening tests are negative may be suffering from an intoxication with a novel psychoactive substance.

TL;DR: This is the first study showing that midazolam pharmacokinetics is linear in a 30,000–fold concentration range, and therefore that nano– and microgram doses of midAZolam can reliably predict the pharmacokinetic of midrazolam in therapeutic doses and can be used to assess CYP3A activity even in the presence of strong CYP2A inhibitors.

TL;DR: The pharmacokinetics of an intravenous midazolam microdose is linear to the applied regular doses and can be used to assess safely systemic CYP3A activity and, in combination with oral microdoses, pre-systemic CYP 3A activity.

TL;DR: This ultrasensitive assay was successfully applied to assess the kinetics of midazolam in two human volunteers after the administration of single oral microgram doses (1–100 μg).